Acrivon Therapeutics Reports $19M Net Loss in Q1 2026, Cash Position Decreases

Acrivon Therapeutics, Inc. reported a net loss of $19.0 million for the first quarter of 2026, a slight improvement from the $19.7 million loss recorded in the same period of 2025. The company's total operating expenses decreased to $19.9 million from $21.7 million year-over-year, primarily due to reduced general and administrative costs, which fell from $6.2 million to $4.7 million. Research and development expenses remained relatively stable, totaling $15.2 million compared to $15.4 million in the prior year. The company has not generated any revenue to date and continues to anticipate ongoing losses as it advances its clinical programs.

As of March 31, 2026, Acrivon held cash, cash equivalents, and investments totaling $97.7 million, down from $120.4 million at the end of 2025. The decrease in cash was attributed to net cash used in operating activities of $20.5 million, which was partially offset by $13.1 million in cash provided by investing activities. The company expects its current cash position, along with recent proceeds of $7.3 million from an at-the-market offering, to fund operations into the third quarter of 2027. However, Acrivon acknowledges the need for additional funding to support its ongoing research and development efforts.

Strategically, Acrivon is advancing its clinical pipeline, which includes ACR-368, a precision oncology asset in a Phase 2b trial for endometrial cancer, and ACR-2316, a dual WEE1/PKMYT1 inhibitor currently in Phase 1/2 studies. The company has received Fast Track designation from the FDA for ACR-368 and is leveraging its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to enhance patient selection and treatment outcomes. Acrivon also recently terminated its companion diagnostic agreement with Akoya Biosciences to bring the development of its ACR-368 OncoSignature test in-house, which is expected to streamline operations and improve efficiency.

In terms of operational metrics, Acrivon reported a weighted average of 38.7 million shares outstanding as of March 31, 2026, compared to 38.4 million shares in the previous year. The company continues to focus on expanding its clinical trials and enhancing its drug development capabilities, with plans to increase research and development expenditures as it progresses through various stages of clinical trials. Acrivon remains committed to its goal of developing precision medicines for oncology, although it acknowledges the inherent risks and uncertainties associated with drug development and the need for substantial additional funding to achieve its objectives.